



(51) International Patent Classification:

A61K 35/17 (2025.01) C12N 5/10 (2006.01)
A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2024/043133

(22) International Filing Date:

21 August 2024 (21.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/520,756 21 August 2023 (21.08.2023) US

(71) Applicant: **CELLEDIT LLC** [US/US]; 100 Barber Avenue, Worcester, Massachusetts 01606 (US).

(72) Inventor: **HU, Biliang**; c/o CELLEDIT LLC, 100 Barber Avenue, Worcester, Massachusetts 01606 (US).

(74) Agent: **CHEN, Yahua**; c/o Mintz Levin, One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CONTROLLED EXPRESSION OF IMMUNE REGULATORY CYTOKINES IN GENETICALLY ENGINEERED IMMUNE CELLS




FIG. 1

(57) Abstract: The present disclosure provides a nucleic acid utilizing intervening self-cleavable peptide linkers (e.g., 2A peptides) to control the expression and/or secretion levels of polypeptides of interest such as immune regulatory agents (e.g., cytokines such as IL-2, IL-15, IL-18 or IL-10), and further provides genetically engineered cells (e.g., T cells) carrying such nucleic acids and therapeutic uses of the genetically engineered cells.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
17 April 2025 (17.04.2025)